FindTrial
Sign In

LY3023414

DRUG12 trials

Sponsors

Eli Lilly and Company, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute

Conditions

Advanced CancerBreast CancerBreast NeoplasmsCancerCarcinoma, Non-small Cell LungCholangiocarcinomaColon CancerColorectal Neoplasms

Phase 1

A Study of LY3023414 in Participants With Advanced Cancer
CompletedNCT01655225
Eli Lilly and CompanyAdvanced Cancer, Malignant Mesothelioma, Metastatic Breast Cancer +3
Start: 2012-07-31End: 2022-02-02Updated: 2022-04-08
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Active, not recruitingNCT02057133
Eli Lilly and CompanyBreast Neoplasms
Start: 2014-03-10End: 2026-12-01Target: 198Updated: 2026-01-26
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
CompletedNCT02079636
Eli Lilly and CompanyCarcinoma, Non-small Cell Lung
Start: 2014-03-28End: 2019-08-29Updated: 2020-09-11
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
CompletedNCT02124148
Eli Lilly and CompanyBreast Cancer, Colorectal Neoplasms, Neoplasm Metastasis
Start: 2014-06-18End: 2020-02-13Updated: 2020-04-01
A Study of LY3023414 in Japanese Participants With Advanced Cancer
CompletedNCT02536586
Eli Lilly and CompanyNeoplasm
Start: 2015-09-30End: 2017-02-09Updated: 2018-07-24
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
TerminatedNCT02784795
Eli Lilly and CompanyBreast Cancer, Cholangiocarcinoma, Colon Cancer +2
Start: 2016-11-04End: 2020-02-13Updated: 2025-08-21

Phase 2

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
CompletedNCT02407054
Eli Lilly and CompanyProstate Cancer Metastatic
Start: 2015-04-29End: 2020-04-16Updated: 2021-05-11
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
TerminatedNCT02443337
Eli Lilly and CompanyNon-small Cell Lung Cancer Metastatic
Start: 2015-07-31End: 2017-09-30Updated: 2020-12-09
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
CompletedNCT02549989
Memorial Sloan Kettering Cancer CenterEndometrial Cancer, Recurrent Endometrial Cancer
Start: 2015-09-30End: 2022-03-23Updated: 2023-02-22
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
CompletedNCT02981342
Eli Lilly and CompanyPancreatic Ductal Adenocarcinoma
Start: 2017-01-12End: 2018-11-09Updated: 2019-11-20
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
RecruitingNCT03675893
Dana-Farber Cancer InstituteEndometrial Cancer, Ovarian Cancer
Start: 2018-12-24End: 2031-08-01Target: 180Updated: 2025-06-15

Unknown Phase

Master Rollover Protocol for Continued Safety Assessment of Study Drug
NCT02632994
Eli Lilly and CompanyCancer
Updated: 2025-09-29

Related Papers

Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.
2025-12-03
Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER)–positive recurrent endometrial cancer (EC).
Journal of Clinical Oncology2025-05-283 citations
Abstract LB_B19: Utilizing genome-informed modeling to assess CDK4/6 inhibitor response in breast cancer patients, simulate clinical trials, and result in novel CDK4/6 inhibitor treatment for chordoma patients
Molecular Cancer Therapeutics2023-12-011 citations
A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.
2022-08-2811 citations
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Clinical Cancer Research2022-04-0142 citations
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
UNC Libraries2022-03-29
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
Frontiers in Oncology2022-02-1015 citations
Abemaciclib in Combination With Pembrolizumab for Stage IV <i>KRAS</i>-Mutant or Squamous NSCLC: A Phase 1b Study.
2021-09-2523 citations
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer.
2021-09-2422 citations
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
2021-03-0828 citations
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
2021-03-0419 citations
Abstract 1761: Inhibition of PI3K/AKT/mTOR signaling by a dual PI3K/mTOR inhibitor (LY3023414) potentiates the antitumor efficacy of the Chk1 inhibitor prexasertib (LY2606368) in models of human high-grade serous ovarian cancer (HGSOC)
Cancer Research2019-07-013 citations
Abstract 3508: Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) models
Cancer Research2019-07-013 citations
Abstract 1761: Inhibition of PI3K/AKT/mTOR signaling by a dual PI3K/mTOR inhibitor (LY3023414) potentiates the antitumor efficacy of the Chk1 inhibitor prexasertib (LY2606368) in models of human high-grade serous ovarian cancer (HGSOC)
Molecular and Cellular Biology / Genetics2019-07-011 citations
Abstract 3508: Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) models
Molecular and Cellular Biology / Genetics2019-07-01
Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.
Journal of Clinical Oncology2019-05-2012 citations
A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.
Journal of Clinical Oncology2019-05-204 citations
Abstract CT020: Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in treatment of patients with advanced mesothelioma
Cancer Research2018-07-01
Updated efficacy, safety, &amp; PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.
Journal of Clinical Oncology2018-05-2040 citations
A phase 1b dose-escalation study of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor, in combination with cisplatin in patients with advanced cancer.
Journal of Clinical Oncology2018-05-205 citations

8 more papers not shown